Plurihormonal Pituitary Adenoma Immunoreactive for Thyroid-Stimulating Hormone, Growth Hormone, Follicle-Stimulating Hormone, and Prolactin

2012 ◽  
Vol 18 (5) ◽  
pp. e121-e126 ◽  
Author(s):  
Cynthia Luk ◽  
Kalman Kovacs ◽  
Fabio Rotondo ◽  
Eva Horvath ◽  
Michael Cusimano ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Pituitary Adenoma ◽  
Follicle Stimulating Hormone ◽  
Thyroid Stimulating Hormone ◽  
Plurihormonal Pituitary Adenoma ◽  
Stimulating Hormone

Pituitary-bone connection in skeletal regulation

2016 ◽  
Vol 28 (2) ◽  
Author(s):  
Mone Zaidi ◽  
Li Sun ◽  
Peng Liu ◽  
Terry F. Davies ◽  
Maria New ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Follicle Stimulating Hormone ◽  
Pituitary Hormones ◽  
Thyroid Stimulating Hormone ◽  
Bone Diseases ◽  
Adrenocorticotrophic Hormone ◽  
Metabolic Bone Diseases ◽  
Metabolic Bone ◽  
Limited Function ◽  
Stimulating Hormone

AbstractPituitary hormones have traditionally been thought to exert specific, but limited function on target tissues. More recently, the discovery of these hormones and their receptors in organs such as the skeleton suggests that pituitary hormones have more ubiquitous functions. Here, we discuss the interaction of growth hormone (GH), follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), adrenocorticotrophic hormone (ACTH), prolactin, oxytocin and arginine vasopressin (AVP) with bone. The direct skeletal action of pituitary hormones therefore provides new insights and therapeutic opportunities for metabolic bone diseases, prominently osteoporosis.

Pituitary failure secondary to head trauma

1976 ◽  
Vol 44 (4) ◽  
pp. 504-505 ◽  
Author(s):  
William W. Winternitz ◽  
James A. Dzur
Keyword(s):  
Growth Hormone ◽  
Head Trauma ◽  
Anterior Pituitary ◽  
Follicle Stimulating Hormone ◽  
Thyroid Stimulating Hormone ◽  
Severe Head Trauma ◽  
Content Type ◽  
Hypothalamic Control ◽  
Fine Print ◽  
Stimulating Hormone

✓ A patient presented with hypopituitarism, 2 years after severe head trauma. Deficits of growth hormone, follicle-stimulating hormone, luteinizing hormone, and borderline thyroid-stimulating hormone (TSH) were demonstrated. Normal TSH-releasing hormone (TRH) response and elevated prolactin indicated viable anterior pituitary tissue with inadequate hypothalamic control. Precautions are suggested for recognition and treatment of this syndrome.

scholarly journals Case Report: A Case of Pituitary Adenoma Producing Growth Hormone and Thyroid-Stimulating Hormone Simultaneously

2021 ◽  
Vol 12 ◽  
Author(s):  
Junpei Sanada ◽  
Fuminori Tatsumi ◽  
Shinji Kamei ◽  
Yoshiro Fushimi ◽  
Masashi Shimoda ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Pituitary Adenoma ◽  
Thyroid Function ◽  
Tumor Resection ◽  
Brain Magnetic Resonance Imaging ◽  
Thyroid Stimulating Hormone ◽  
Clinical Findings ◽  
Additional Treatment ◽  
Pituitary Fossa ◽  
Stimulating Hormone

BackgroundPituitary adenoma producing growth hormone (GH) or thyroid-stimulating hormone (TSH) is characterized by various specific symptoms and/or findings. However, the frequency of pituitary adenoma producing both hormones is relatively low. In this report, we show a case of pituitary adenoma producing both GH and TSH simultaneously.Case presentationA 27-year-old woman was diagnosed as acromegaly based on various symptoms and clinical findings. For further examination and treatment, she was hospitalized in our institution. It was likely that this subject had pituitary adenoma producing both GH and TSH. In brain magnetic resonance imaging, there was a giant tumor around pituitary fossa. After the diagnosis of GH- and TSH-producing pituitary adenoma, pituitary tumor resection and cyber knife therapy were performed. In addition, we started additional treatment with somatostatin analog and GH receptor antagonist. After then, GH and insulin-like growth factor (IGF-1) levels were suppressed. After the operation, since thyroid function was not sufficiently suppressed, we started anti-thyroid drug thiamazole. After then, thyroid function was normalized and we stopped thiamazole. In GH and TSH staining, many GH-positive and TSH-positive cells were observed. These findings further confirmed our diagnosis that the pituitary adenoma in this subject produced both GH and TSH simultaneously.ConclusionsWe should bear in mind the possibility of pituitary adenoma producing both GH and TSH at the same time.

ELECTROPHORETIC SEPARATION OF HORMONES ASSOCIATED WITH SECRETORY GRANULES FROM RAT ANTERIOR PITUITARY GLANDS

1970 ◽  
Vol 63 (2) ◽  
pp. 378-384 ◽  
Author(s):  
D. R. Hodges ◽  
W. H. McShan
Keyword(s):  
Growth Hormone ◽  
Anterior Pituitary ◽  
Secretory Granules ◽  
Follicle Stimulating Hormone ◽  
Pituitary Hormones ◽  
Thyroid Stimulating Hormone ◽  
Disc Electrophoresis ◽  
Hormone Activity ◽  
Pituitary Glands ◽  
Stimulating Hormone

ABSTRACT Electrophoretic analyses of rat, mouse, human and cow anterior pituitary homogenates with subsequent bioassays for hormonal activity have been reported. Comparison of the behaviour of the hormonal activities from rat anterior pituitary secretory granules and that reported for pituitary homogenates was made following disc electrophoresis on polyacrylamide gels. Bioassays of gel segments for the six anterior pituitary hormones resulted in the localization of the activities of five of the six hormones. ACTH activity was not detected. Growth hormone and prolactin were associated with the major cathodal and anodal discs respectively. Luteinizing hormone and thyroid stimulating hormone activities had similar mobilities and were located in a zone just above growth hormone. The activity was not restricted to a discrete, stainable disc in either case. Follicle stimulating hormone activity was detected in a narrow segment containing only one disc a few millimeters below growth hormone. Comparison of the mobilities of the hormones from homogenates and secretory granule extracts suggests that they have essentially similar electrophoretic characteristics at basis pH.

scholarly journals Significance of hyperprolactinemia for cytomorphologic features of breast secretions

2010 ◽  
Vol 67 (1) ◽  
pp. 42-47
Author(s):  
Danijela Radojkovic ◽  
Slobodan Antic ◽  
Milica Pesic ◽  
Milan Radojkovic ◽  
Dijana Basic ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Nipple Discharge ◽  
Thyroid Stimulating Hormone ◽  
Serum Prolactin ◽  
Control Group ◽  
Clinical Group ◽  
Group I ◽  
Stimulating Hormone

Background/Aim. Nipple discharge syndrome is a clinical entity capable of presenting various disorders such is mammary infection (nonpuerperal and puerperal mastitis), intraductal papillomas, fibrodenoma, breast cancer and hyperprolactinemia syndrome. The aim of the study was to determine differencies in cytological features of mammary secretion in patients with hyperprolactinemia and those with normal serum prolactin levels and to define the role of growth hormone, follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone in creating cellular profile of breast secretion. Methods. The study included 50 patients with nipple discharge syndrome. The patients were devided into the clinical group (27 patients with hyperprolactinemia and nipple discharge) and the control group I (23 patients with normal serum prolactin and nipple discharge). The control group II included the patients of the clinical group achiving normalised serum prolactin levels after the treatment of hyperprolactinemia. Serum prolactin, follicle-stimulating hormone and luteinizing hormone levels were assessed by RIA using commercial kits IRMA hPRL, hLH and hFSH, (INEP, Zemun, Serbia) while serum growth hormone and thyroid-stimulating hormone levels were assessed by RIA using commercial kits LKB-wallac. Cytologic evaluation of samples, taken from all the patients with mammary secretion, was done using standard techniques of staining Haemathoxilin-eozine and May- Gr?nwald/Giemsa. Results. Our results showed a significantly higher presence of lipid and protein material in clinical group, in comparison with the control group I (p < 0.01). Also, our data demonstrated significantly higher number of ductal epithelial cells (p < 0.05) and ductal histiocities (p < 0.001) in the clinical group, compared with the control group I. Macrophagies frequency was proportionally higher in clinical group (44.44%) compared the control group I (17.39%). Erythrocites were significantly lower in the clinical group (p < 0.001) than in the control group I. Significantly decreased mammary secretion (p < 0.01), lower lipid (p < 0.01) and protein synthesis (p < 0.01), and less presence of all cellular categories (p < 0.01) were obtained after normalization of serum prolactin levels. Conclusion. Growth hormone, follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone did not show significant influence on creating cytological features of mammary secretion. The most expressive role, hyperprolactinemia demonstrated in the domain of mammary ductal secretory activity, making mammary secretion reach in lipid and protein material and simultaneously increasing number of ductal epithelial cells, ductal histiocytes and 'foam cells'- macrophages. These cytological findings indicate that hyperprolactinemia promote periductal and intraductal steril inflammation which withdraws after serum prolactin normalization.

Sign in / Sign up

Export Citation Format

Share Document